With a new CEO at the helm and its hematological program still under a clinical hold, Fulcrum Therapeutics has signed a licensing and discovery deal with RNA startup Camp4 Therapeutics to develop a treatment for a rare blood disorder.
Diamond-Blackfan anemia is a congenital disease that affects around 5,000 people worldwide, Fulcrum wrote in a press release Monday. Patients who have the disease, usually diagnosed at birth, can be treated with steroids and blood transfusions, according to Boston Children’s Hospital. The only known cure is a stem cell transplant.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters